Screener
Vaxcyte, Inc. PCVX Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 352,294 | 317,207 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' Equity | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 147 | 134 |
| Additional paid-in capital | 5,478,270 | 4,838,736 |
| Accumulated other comprehensive loss | (6,834) | 1,587 |
| Accumulated deficit | (2,475,569) | (2,154,947) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s preferred stock, shares authorized?
- Vaxcyte, Inc. (PCVX) reported preferred stock, shares authorized of $10M in Q1 2026.
- How has Vaxcyte, Inc.'s preferred stock, shares authorized changed year-over-year?
- Vaxcyte, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
- What is the long-term trend for Vaxcyte, Inc.'s preferred stock, shares authorized?
- Over 2 years (2023 to 2025), Vaxcyte, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
Ask your AI about Vaxcyte, Inc.'s preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude